BACKGROUND: Galectin-3 (Gal-3) is a β-galactoside-binding lectin involved in regulating cell growth, angiogenesis, and tumor progression. We investigated the clinical significance of Gal-3 expression including its possible use as a prognostic marker or therapeutic target in epithelial ovarian carcinoma (EOC). METHODS: Gal-3 expression was evaluated by immunohistochemistry in 71 patients with 54 serous, 13 endometrioid, and 4 mucinous ovarian carcinomas. We assessed the correlation of Gal-3 expression with clinical characteristics including histology, optimal debulking, chemosensitivity, and survival. In vitro, Gal-3 was inhibited using siRNA to evaluate its role in cell growth and sensitivity to chemotherapeutic agents in ovarian carcinoma cell lines. RESULTS: Gal-3 protein, which was mainly cytoplasmic in location, was observed in a majority (63/71, 88.7%) of the EOCs but not in normal ovarian tissues (P < 0.001). High Gal-3 expression in EOCs correlated with shorter progression-free survival (PFS) of patients (P = 0.039; 43.1 and 49.5 months, respectively). Moreover, cotreatment with Gal-3 siRNA and paclitaxel showed an enhanced cytotoxic effect compared with control siRNA in SKOV3 cells. CONCLUSION: These findings suggest that Gal-3 expression can be a prognostic factor for PFS and may be involved in regulating the response to paclitaxel-based chemotherapy in the treatment of EOC.
BACKGROUND:Galectin-3 (Gal-3) is a β-galactoside-binding lectin involved in regulating cell growth, angiogenesis, and tumor progression. We investigated the clinical significance of Gal-3 expression including its possible use as a prognostic marker or therapeutic target in epithelial ovarian carcinoma (EOC). METHODS:Gal-3 expression was evaluated by immunohistochemistry in 71 patients with 54 serous, 13 endometrioid, and 4 mucinous ovarian carcinomas. We assessed the correlation of Gal-3 expression with clinical characteristics including histology, optimal debulking, chemosensitivity, and survival. In vitro, Gal-3 was inhibited using siRNA to evaluate its role in cell growth and sensitivity to chemotherapeutic agents in ovarian carcinoma cell lines. RESULTS:Gal-3 protein, which was mainly cytoplasmic in location, was observed in a majority (63/71, 88.7%) of the EOCs but not in normal ovarian tissues (P < 0.001). High Gal-3 expression in EOCs correlated with shorter progression-free survival (PFS) of patients (P = 0.039; 43.1 and 49.5 months, respectively). Moreover, cotreatment with Gal-3 siRNA and paclitaxel showed an enhanced cytotoxic effect compared with control siRNA in SKOV3 cells. CONCLUSION: These findings suggest that Gal-3 expression can be a prognostic factor for PFS and may be involved in regulating the response to paclitaxel-based chemotherapy in the treatment of EOC.
Authors: Pratima Nangia-Makker; Victor Hogan; Yuichiro Honjo; Sara Baccarini; Larry Tait; Robert Bresalier; Avraham Raz Journal: J Natl Cancer Inst Date: 2002-12-18 Impact factor: 13.506
Authors: T Oishi; H Itamochi; J Kigawa; Y Kanamori; M Shimada; M Takahashi; R Shimogai; W Kawaguchi; S Sato; N Terakawa Journal: Int J Gynecol Cancer Date: 2007-04-12 Impact factor: 3.437
Authors: Sunil R Hingorani; Michael A Jacobetz; Gavin P Robertson; Meenhard Herlyn; David A Tuveson Journal: Cancer Res Date: 2003-09-01 Impact factor: 12.701
Authors: Vladislav V Glinsky; Galina Kiriakova; Olga V Glinskii; Valeri V Mossine; Thomas P Mawhinney; James R Turk; Anna B Glinskii; Virginia H Huxley; Janet E Price; Gennadi V Glinsky Journal: Neoplasia Date: 2009-09 Impact factor: 5.715
Authors: Judith S Knapp; Soum D Lokeshwar; Ulrich Vogel; Jörg Hennenlotter; Christian Schwentner; Mario W Kramer; Arnulf Stenzl; Axel S Merseburger Journal: World J Urol Date: 2012-08-15 Impact factor: 4.226
Authors: H Yilmaz; H T Celik; O Ozdemir; D Kalkan; M Namuslu; S Abusoglu; C R Atalay; R Yigitoglu Journal: J Endocrinol Invest Date: 2014-01-09 Impact factor: 4.256
Authors: V Veschi; M Petroni; A Bartolazzi; P Altavista; C Dominici; C Capalbo; R Boldrini; A Castellano; H P McDowell; B Pizer; L Frati; I Screpanti; A Gulino; G Giannini Journal: Cell Death Dis Date: 2014-03-06 Impact factor: 8.469
Authors: Emanuela Anastasi; Silvia Gigli; Maria Santulli; Sara Tartaglione; Laura Ballesio; Maria Grazia Porpora; Teresa Granato; Carlo Catalano; Antonio Angeloni; Lucia Manganaro Journal: Asian Pac J Cancer Prev Date: 2017-05-01